Ars Technica1 min read
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Markers released top-line results today after previously reporting the trial succeeded.
By Beth MoleArs Technica

Read the full story
Originally published by Ars Technica on Oct 22, 2026.
Comments
Sign in to join the discussion.